Target therapy in metastatic renal cell carcinoma

European Journal of Cancer, Supplement

Volumn 6, Issue 14, 2008, Pages 38-41

  Carteni G ^a   Grimaldi, A M ^b   Guida, T ^a   Riccardi, F ^a   Biglietto, M ^a   Perrotta, E ^a   Otero, M ^a   De Rosa, P ^a   Nicolella, G ^a   Esposito, G ^a   Fiorentino, R ^a   Chiurazzi, B ^a   Battista, C ^a   Panza, N ^a  

^a Division of Medical Oncology A   (Italy)

^b AO S Carlo   (Italy)

Author keywords

Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; INTERFERON; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; NEPHRECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RASH; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 55649122294     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2008.06.022     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 (2005) 1028-1043
3. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
4. Escudier B., Koralewski P., Pluzanska A., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon-2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25 (2007) 3
5. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
6. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388S-6392S
7. Wilhelm S.M., Carter C., Tang L., et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
8. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356 (2007) 125-134
10. Szczylik C., Demkow T., Staehler M., et al. Randomized phase II trial of firstline treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25 (2007) 5025
11. Ryan C., Bukowski R., Figlin R., et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in firstline patients (pts). J Clin Oncol 25 (2007) 5096
12. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
13. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
14. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
15. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356 (2007) 115-124
16. Sablin M.P., Bouaita L., Balleyguier C., et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 25 (2007) 5038
17. Graff J.R., and Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20 (2003) 265-273
18. Kenerson H.L., Aicher L.D., True L.D., et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
19. Kondo K., Yao M., Kobayashi K., et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 91 (2001) 219-224
20. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
21. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
22. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281